Race Oncology is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart.It hopes to address the high unmet need of patients across multiple oncology indications by making use of the unique mechanisms of action of our drug, bisantrene.Bisantrene, is a small molecule anthracene-based chemotherapeutic that has compelling clinical data demonstrating anti-cancer and cardio-protection… Show more Race Oncology is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart.It hopes to address the high unmet need of patients across multiple oncology indications by making use of the unique mechanisms of action of our drug, bisantrene.Bisantrene, is a small molecule anthracene-based chemotherapeutic that has compelling clinical data demonstrating anti-cancer and cardio-protection effects. Originally developed in the 1970s and 1980’s with the goal of creating a less cardiotoxic, anthracycline-like chemotherapeutic, bisantrene has demonstrated efficacy and a well characterised safety profile having been evaluated in more than 46 clinical trials, and 70 peer reviewed publications, with over 1.8k patients treated. More recently, evidence has emerged that bisantrene is also cardioprotective, offering another potentially significant benefit to patients.Leveraging the drug’s rich clinical history, Race is now taking the new bisantrene into two substantial areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).Led by a highly experienced and passionate leadership team who are supported by a panel of expert global advisors, Race Oncology’s business strategy has evolved to take advantage of recent clinical insights and new preclinical programmes initiated in-house. Show less

Cytomatrix has developed a proprietary biocompatible polymeric delivery technology (Short Polymer Fibres - SPFs) that enables us to sustain the release of a range of molecular types, including proteins, peptides, RNA, DNA, small molecules and ionic compounds. Release rates can be controlled from days through to months, via alterations to the biodegradable polymer compositions. Applications of the technology include vaccines and therapeutics for enhanced, longer-term efficacy, for both humans… Show more Cytomatrix has developed a proprietary biocompatible polymeric delivery technology (Short Polymer Fibres - SPFs) that enables us to sustain the release of a range of molecular types, including proteins, peptides, RNA, DNA, small molecules and ionic compounds. Release rates can be controlled from days through to months, via alterations to the biodegradable polymer compositions. Applications of the technology include vaccines and therapeutics for enhanced, longer-term efficacy, for both humans and animals. The company's lead asset is an anticancer vaccine, which we have shown can drive a far stronger immune response compared to the traditional approach. Cytomatrix will combine this vaccine with other treatment modalities in a rational fashion and with personalised immune monitoring to optimise therapy delivery and boost patient outcomes. The anticancer vaccine has been through a program of rigorous testing with partners at Deakin University and CSIRO and is nearing entry into a Phase I/II study in cancer patients. Show less

Ecobiotics/QBiotics develops new therapeutics, nutraceuticals, functional foods and cosmetics from naturally-occuring compounds found in the rainforests of North Queensland. My role is to coordinate the development of therapeutics for treating diseases, such as cancer, by managing manufacturing, shipping, preclinical testing and clinical trials of the company's new compounds. This necessitates management of vendor relationships, leadership of the internal team at QBiotics, and overall… Show more Ecobiotics/QBiotics develops new therapeutics, nutraceuticals, functional foods and cosmetics from naturally-occuring compounds found in the rainforests of North Queensland. My role is to coordinate the development of therapeutics for treating diseases, such as cancer, by managing manufacturing, shipping, preclinical testing and clinical trials of the company's new compounds. This necessitates management of vendor relationships, leadership of the internal team at QBiotics, and overall responsibility for the general conduct of the company's multi-million dollar programmes. Show less

We work with people who have ideas, know what they want, but who also want someone to help them along the journey. We provide business know-how, along with an extensive network of professionals, to accelerate your venture, and to satisfy your ambition.

Managing an ICT project for the School of Chemical and Molecular Biosciences, aimed at First Year students. Will combine a web interface and content management system linked to a database of scenario tasks that students will undertake in groups. Supported by the Australian Teaching and Learning Council.

LifeHaler is developing a unique, new, wearable and waterproof asthma medication delivery device to free asthmatics from the fear of losing their inhaler or not being able to access it during an attack.

Tutoring in Business Growth to 3rd Year students

Managed BNC105 manufacturing, preclinical testing and preparations for Phase I clinical trial.

Responsible for preclinical development of company's lead compound, Xen2174. Supported clinical trial of Xen2174.

Responsible for synthesising and testing new potential drug molecules,

Member of New Projects team, testing new formulations of generic drugs.